Advances in Systemic Treatment Options for Prurigo Nodularis

Video content above is prompted by the following:

• Priorto the FDA approval of 2 systemic treatment options for PN, what was your typical treatment approach for patients with PN? At what point would systemic therapy be considered for a patient?
• How has this treatment approach changed in recent years after the FDA approval of biologic systemic treatments for PN? In your opinion, what is the role in therapy for these agents?
• Briefly discuss the 2 agents that are currently FDA-approved for PN, including how they work to address itch and skin lesions, as well as efficacy and safety data.
  • Dupilumab
  • Nemolizumab

• Discuss other systemic therapies in the pipeline for the treatment of prurigo nodularis (eg, Janus kinase inhibitors).